Search Results for leukemia, aml, multiple myeloma

..., secondary acute myeloid leukemia; TSG, tumor suppressor gene. Several studies have explored the role of ADAR in acute myeloid leukemia (AML). 31 , 113 In 2000, researchers found that protein tyrosine phosphatase nonreceptor type 6 (PTPN6), known for splicing mutations in hematopoietic...

.... Each symbol represents an individual patient. Two group comparison 750 was done using ordinary one-way ANOVA using Sidak s multiple comparison. (G) Indicated T 751 cell subset changes of respective disease entities including acute myeloid leukemia (AML) 752 were normalized to the mean of their own...

... hematological 121 malignancies, including acute myeloid leukemia (AML)16,17 and B-cell non-Hodgkin 122 lymphomas18, as well as solid tumors including renal cell carcinoma19 and non-small cell lung 123 cancer20. Unifying mechanisms underlying CD70 upregulation across cancers remain unclear, 124 although...

... in accelerated phase. Clin Lymphoma Myeloma 603 Leuk. 2014;14(2):155-162.e1. 604 76. Jiang Q, Yu L, Qin Y-Z, Lai Y-Y, Huang X-J. Comparison of the Outcome between Newly 605 Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia 606 Treated with Frontline Tyrosine Kinase...

... of the hematopoietic stem cell (HSC) factor GATA2 to chemotherapy resistance in acute myeloid leukemia (AML) and reported an original molecular link between GATA2 and TP53 through the inhibition of the MDM2 modulator RASSF4. AML remains an unmet medical need with up to 40% of pediatric patients experiencing...

... CD34+ cell dose (×10E6/kg) 7.2 [5.6-8.4] 7.3 [5.6-8.5] 6.4 [5.4-8.0] 0.35 Follow-up Years 4.8 [3.0-5.3] 3.6 [2.0-4.8] 11.6 [9.2-13.4] <0.01 ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; B-NHL = B-cell non-Hodgkin lymphoma; CLL = chronic lymphocytic leukemia; CML = chronic myeloid...

... such as the original 4 and revised (R) 5 International Prognostic Scoring Systems (IPSS) risk-stratify patients with MDS to help estimate the chances of progression into acute myeloid leukemia (AML) and account for the depth of cytopenia. However, these tools rely solely on clinical, morphological...

... Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK-cell function with oncological drugs could improve NK-cell–based immunotherapies. Here, we used a high-throughput drug screen...

... treatment by the investigator. Two were acute myeloid leukemia (AML), which were diagnosed at 2 and 10 months after prizlon-cel infusion. Flow cytometry was conducted on 1 patient's peripheral blood sample after AML diagnosis, revealing no CAR expression in CD45 dim /CD33 + AML cells. One 60-year-old...

...: Mean gene set score from all subjects by cluster. F: PRETX frequency of exhausted-like/exhausted T cells quantified by single-cell sequencing, including public data,25,30 32 and separated by tumor type; p calculated by Wilcoxon rank sum test. AML=acute myeloid leukemia; CRC=colorectal cancer; LC=lung...

... benefit selected patients not undergoing allogeneic transplant, while exploring the many unanswered questions that arise in clinical practice. Over the past decade, there have been multiple new drug approvals to treat acute myeloid leukemia (AML). 1 Although the original nonselective cytotoxic...

...Andrew H. Wei; Sun Loo; Naval Daver Venetoclax (VEN) received full approval in October 2020 for use in older patients who are unfit with acute myeloid leukemia (AML) combined with either hypomethylating agents or low-dose cytarabine. This ended a semicentennial of stalled clinical progress...

...Steven D. Green; Eunice S. Wang Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or after prior cytotoxic or radiation therapy. We now know sAML comprises multiple disease entities with distinct clinical...

..., demonstrated even greater anti-leukemic activity than AZ2 across multiple AML cell lines and primary leukemia samples32. ARM165 also showed synergy in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Thus, AZ2 and/or ARM165 might be promising PI3K inhibitors to be tested clinically...

..., Gjertsen BT, McCormack E, et al. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2008;111(5):2866 2877. Mill CP, Fiskus W, DiNardo CD, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation...

... Prognostic Scoring System-Revised groups of very high, high, and, sometimes, intermediate (score >3.5, though in this trial it was defined as a score >3). 2 HR-MDS is a disease of older age, fraught with the risk of impending transformation to acute myeloid leukemia (AML), disease-related...

... ozogamicin in acute myeloid leukemia (AML). 37 This result highlights the importance of the BCL2 apoptosis pathway in calicheamicin resistance, regardless of the targeting antigen used in AML vs ALL. Interestingly, the loss of DNTT was found to be the third most significant determinant of InO resistance...

... Kojouri; Jacob S Appelbaum; Mary-Elizabeth M. Percival; Brenda M Sandmaier; Stephanie J. Lee; Frederick Appelbaum; Rayne H. Rouce; Mohamed L. Sorror Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants...

... hematologic malignancies, including R/R acute lymphoblastic leukemia (ALL), B-cell lymphoma, and multiple myeloma. 7-13 The potential of CAR-T therapy in managing AML has garnered significant interest recently, with many investigations in the preclinical phase. 14-21 A comprehensive review of CAR-T...

... of the human CSF1R, KIT, and FLT3-ITD kinases Evaluated in phase 1/2 study for activity in relapsed/refractory FLT3-ITD–mutant AML (NCT01349049) 41 Evaluated for maximum tolerable dose in phase 1 trial for pediatric refractory leukemias (NCT02390752) 42 Edicotinib (JNJ-40346527) Experimental...